B. Riley Brokers Increase Earnings Estimates for VRDN

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Equities research analysts at B. Riley upped their Q2 2025 EPS estimates for Viridian Therapeutics in a research report issued on Tuesday, May 6th. B. Riley analyst K. Patel now expects that the company will post earnings per share of ($0.91) for the quarter, up from their previous forecast of ($1.14). The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($4.03) per share. B. Riley also issued estimates for Viridian Therapeutics’ Q3 2025 earnings at ($0.97) EPS, Q4 2025 earnings at ($1.04) EPS, FY2025 earnings at ($3.79) EPS, FY2026 earnings at ($4.01) EPS and FY2027 earnings at ($3.04) EPS.

Viridian Therapeutics (NASDAQ:VRDN) last posted its earnings results on Tuesday, May 6th. The company reported ($0.87) earnings per share for the quarter, beating the consensus estimate of ($0.95) by $0.08. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The company had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.16 million. The business’s revenue for the quarter was up .0% compared to the same quarter last year.

Other equities research analysts have also recently issued reports about the stock. Needham & Company LLC decreased their price target on shares of Viridian Therapeutics from $38.00 to $36.00 and set a “buy” rating on the stock in a research note on Wednesday. Royal Bank of Canada dropped their price target on shares of Viridian Therapeutics from $46.00 to $45.00 and set an “outperform” rating for the company in a research report on Wednesday. JMP Securities reduced their price objective on Viridian Therapeutics from $42.00 to $38.00 and set a “market outperform” rating on the stock in a research note on Wednesday. HC Wainwright reiterated a “buy” rating and set a $34.00 price objective on shares of Viridian Therapeutics in a research note on Wednesday, April 23rd. Finally, The Goldman Sachs Group lowered their price target on shares of Viridian Therapeutics from $31.00 to $27.00 and set a “buy” rating for the company in a report on Wednesday. One analyst has rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $36.70.

Viridian Therapeutics Trading Down 1.9 %

Shares of VRDN opened at $12.54 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55. The firm has a 50 day simple moving average of $13.71 and a 200-day simple moving average of $17.53. The stock has a market cap of $1.02 billion, a price-to-earnings ratio of -2.91 and a beta of 0.57. Viridian Therapeutics has a 1-year low of $9.90 and a 1-year high of $27.20.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in VRDN. DCF Advisers LLC boosted its position in shares of Viridian Therapeutics by 108.5% during the first quarter. DCF Advisers LLC now owns 62,029 shares of the company’s stock worth $836,000 after buying an additional 32,279 shares during the period. J. Safra Sarasin Holding AG lifted its holdings in shares of Viridian Therapeutics by 99.4% in the first quarter. J. Safra Sarasin Holding AG now owns 72,672 shares of the company’s stock valued at $980,000 after buying an additional 36,219 shares during the period. Knights of Columbus Asset Advisors LLC boosted its position in shares of Viridian Therapeutics by 2.7% during the 1st quarter. Knights of Columbus Asset Advisors LLC now owns 59,281 shares of the company’s stock valued at $799,000 after purchasing an additional 1,570 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in Viridian Therapeutics by 34.7% during the first quarter. Victory Capital Management Inc. now owns 552,850 shares of the company’s stock worth $7,452,000 after buying an additional 142,410 shares in the last quarter. Finally, Rice Hall James & Associates LLC boosted its stake in shares of Viridian Therapeutics by 579.9% during the 1st quarter. Rice Hall James & Associates LLC now owns 362,893 shares of the company’s stock worth $4,892,000 after acquiring an additional 309,518 shares in the last quarter.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.